Filings
| Filing | Date | Type | Filed with |
|---|
| Next Day Disclosure Return | Nov 19, 2026 | Next day disclosure return | HKEX |
|---|
| INSIDE INFORMATION ANNOUNCEMENT
COMPLETION OF THE H SHARE FULL CIRCULATION | Nov 19, 2026 | Other filings | HKEX |
|---|
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026 | Nov 3, 2026 | Monthly return | HKEX |
|---|
| Next Day Disclosure Return | Nov 2, 2026 | Next day disclosure return | HKEX |
|---|
| INSIDE INFORMATION ANNOUNCEMENT
GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR
IMPLEMENTATION OF THE H SHARE FULL CIRCULATION | Nov 1, 2026 | Other filings | HKEX |
|---|
| Next Day Disclosure Return | Oct 27, 2026 | Next day disclosure return | HKEX |
|---|
| INSIDE INFORMATION ANNOUNCEMENT
ISSUANCE OF THE FILING NOTICE BY THE CSRC FOR THE H SHARE
FULL CIRCULATION BY THE COMPANY | Oct 26, 2026 | Other filings | HKEX |
|---|
| Next Day Disclosure Return | Oct 26, 2026 | Next day disclosure return | HKEX |
|---|
| Next Day Disclosure Return | Oct 23, 2026 | Next day disclosure return | HKEX |
|---|
| Next Day Disclosure Return | Oct 22, 2026 | Next day disclosure return | HKEX |
|---|
| VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE ON COMMERCIALISATION OF CORE PRODUCT
YOCHANRA | Oct 22, 2026 | Operations update | HKEX |
|---|
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026 | Oct 5, 2026 | Monthly return | HKEX |
|---|
| INTERIM REPORT 2026 | Sep 21, 2026 | Interim report | HKEX |
|---|
| VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH NOVEL HORMONAL THERAPY FOR PRETREATED AND PROGRESSED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHINA | Sep 18, 2026 | Operations update | HKEX |
|---|
| VOLUNTARY ANNOUNCEMENT INCLUSION OF YOCHANRA (TINENGOTINIB) IN THE CSCO GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF BILIARY TRACT CANCERS (2026) | Sep 18, 2026 | Other filings | HKEX |
|---|